Based on a disruptive nanotechnology, Abionic is revolutionizing the world of in vitro diagnostics with rapid universal point-of-care solutions.
Abionic is committed to revolutionizing the world of in vitro diagnostics with rapid universal point-of-care solutions.
Abionic develops and produces rapid blood tests that are game-changing in each of their respective markets. There is a significant need for a rapid and accurate test that will enable treatment faster. Furthermore, the solution allows access to lab quality blood analysis where there is no or no sufficient infrastructure in place.
Healthcare professionals and patients can benefit from Abionic’s unique solution to aid in the diagnosis and screening of diverse conditions with an immediate quantitative result.
Abionic has been ranked best Swiss Start-up in MedTech category in 2012, 2013 and 2014 by the startup.ch jury, and is often referred to as an example of business development and organization within the Swiss start-ups’ community. Record-winner of more than 20 awards, Abionic is proud to be broadly recognized for its scientific and management achievements:
I invested in Abionic years back as the vision was amazing for humankind. The founders of Abionic are indeed exceptionally skilled and motivated and dedicated to making the difference in this world. It's an amazing feeling that today Abionic most likely will be able to save millions on yearly basis.
Abionic is proud to have received the following awards and achievements:
